The Pharmapolis Innovative Pharmaceutical Cluster was established in 2005 with the support of the University of Debrecen, the Municipality of Debrecen, and member companies of the Hajdú-Bihar County Chamber of Commerce and Industry, expressing their intention to work together to promote industrial networking by leveraging the region’s strengths. The cluster brought together pharmaceutical industry stakeholders in the region, who decided to collaborate on coordinated R&D activities. The Pharmapolis Cluster had multiple objectives: on the one hand, it sought to strengthen the less developed elements of the Hungarian pharmaceutical industry’s innovation chain in line with the export interests of economic stake-holders, and on the other hand, it aimed to contribute to enhancing European innovation capacities. They sought to achieve these goals by adapting the pharmaceutical-specific elements of the European Technology Platforms.
The vision of the Pharmapolis cluster was to establish pharmaceutical cooperation on a significant international scale, which contributed significantly to boosting economic performance and expanding employment. Through its positive externalities, the cluster also had a beneficial impact on the Hungarian economy as a whole.
As outlined in the strategic and action plan of the Pharmapolis Innovative Pharmaceutical Cluster, it was fully aligned with the overarching goals of the then-current Hungarian Pole Program:
- Promoting the development of internationally competitive clusters
- Specialization in high-value-added, innovative activities
- Strengthening cooperation primarily among businesses, and secondarily among universities and local governments, to maintain long-term competitiveness
- Strengthening the regional hub role of key cities, thereby improving the overall competitiveness and business environment of these hubs
Through connections among the pharmaceutical and biotechnology companies within the cluster, as well as cooperation with the research and university sectors, they have achieved the scale necessary for European-level competitiveness and strengthened high-value-added, export-oriented activities, thereby significantly increasing the competitiveness of the entire Hungarian economy. Contributing to this has been the development of universities and educational institutions, as well as health and cultural services, in line with the objectives of the Pole Program.
The Pharmapolis Debrecen Innovative Pharmaceutical Cluster places great emphasis on ensuring that new, innovative products are developed through its research and development collaborations, and that the R&D&I&O activities conducted by member organizations and their results are widely disseminated.
Businesses in the region have now accepted, recognized, and come to rely on the university’s role as a knowledge-sharing hub for the pharmaceutical industry—a role that has been in practice for nearly two decades—by capitalizing on the opportunities inherent in cooperation and realizing the potential of the quadruple helix model.
Another key objective of the cluster is to continue operating as an innovation cluster in the future, providing priority support to small and medium-sized enterprises and large corporations operating in the pharmaceutical and healthcare sectors, thereby strengthening their R&D potential.
The cluster’s focus areas were identified based on the city’s and the university’s strengths, as well as the development directions, trends, results, and experiences of recent years, which served as the basis for defining the cluster’s medium- and long-term goals. One of the cluster’s main goals is to contribute to the region’s economic growth by fostering cooperation among its members.